Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (06990) has entered into a structured deposit agreement with Bank of China, committing to invest RMB 440 million in structured deposits, which are expected to yield higher returns than traditional bank deposits [1] Summary by Relevant Sections - Investment Details - The company has agreed to subscribe to structured deposits amounting to RMB 440 million with Bank of China [1] - The structured deposits are characterized as capital-protected financial products with floating returns [1] - Expected Benefits - The anticipated return rate from these structured deposits is expected to exceed that of general commercial bank deposits [1] - This investment is aimed at improving the efficiency of the company's idle funds [1] - Management's Perspective - The board believes that the terms of the structured deposit agreement are fair and reasonable [1] - The investment aligns with the overall interests of the company's shareholders [1]